Aerie Pharmaceuticals (NASDAQ:AERI) had its price objective hoisted by equities researchers at Canaccord Genuity from $73.00 to $86.00 in a research note issued on Thursday, January 25th, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price objective points to a potential upside of 50.48% from the company’s current price.

Several other equities research analysts have also issued reports on AERI. Cowen restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. Mizuho reiterated a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Monday, October 2nd. Guggenheim began coverage on shares of Aerie Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $80.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $76.00 price target (up from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Finally, JMP Securities set a $68.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 11th. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $73.27.

Aerie Pharmaceuticals (AERI) opened at $57.15 on Thursday. The stock has a market cap of $2,067.50 and a PE ratio of -17.11. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 1 year low of $38.14 and a 1 year high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.89) earnings per share for the quarter. research analysts forecast that Aerie Pharmaceuticals will post -3.97 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in AERI. Moody Aldrich Partners LLC grew its stake in Aerie Pharmaceuticals by 48.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 31,956 shares of the company’s stock valued at $1,909,000 after acquiring an additional 10,430 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in Aerie Pharmaceuticals by 14.4% during the fourth quarter. Rice Hall James & Associates LLC now owns 269,161 shares of the company’s stock valued at $16,082,000 after purchasing an additional 33,927 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Aerie Pharmaceuticals by 7.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 164,605 shares of the company’s stock valued at $9,836,000 after purchasing an additional 11,937 shares during the last quarter. GSA Capital Partners LLP lifted its position in Aerie Pharmaceuticals by 31.3% during the third quarter. GSA Capital Partners LLP now owns 6,444 shares of the company’s stock valued at $313,000 after purchasing an additional 1,538 shares during the last quarter. Finally, Iguana Healthcare Management LLC lifted its position in Aerie Pharmaceuticals by 5.3% during the third quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the company’s stock valued at $4,860,000 after purchasing an additional 5,000 shares during the last quarter.

WARNING: This story was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2018/01/29/canaccord-genuity-reiterates-buy-rating-for-aerie-pharmaceuticals-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.